Loading

Vaxxas

June 04, 2024
Company Presentation
Medical Devices
Company Presentation Theater 3
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious diseases and oncology. With success in several completed human clinical trials involving more than 500 participants; additional ongoing Phase I clinical studies for COVID-19 and seasonal influenza; and other vaccine studies targeting pandemic influenza, funded by the United States Biomedical Advanced Research and Development Authority (BARDA), a typhoid vaccine patch study funded by the Wellcome Trust, and a measles and rubella vaccine patch program supported by the Bill and Melinda Gates Foundation, Vaxxas’ HD-MAP vaccine delivery platform is advancing rapidly toward commercialization.
Vaxxas
Company Website: https://www.vaxxas.com/
Lead Product in Development: Influenza vaccine administered using high-density microarray patch

Company HQ City

Cambridge

Company HQ State

MA

Company HQ Country

United States

CEO/Top Company Official

David Hoey

Development Phase of Primary Product

Phase I
Speakers
David Hoey, BS
Chief Executive Officer
Vaxxas
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS